●Call for Papers: Volume 16, Issue 2 — Submit by March-April 2026●Open Access — All articles freely available worldwide●Call for Papers: Volume 16, Issue 2 — Submit by March-April 2026●Open Access — All articles freely available worldwide
Journal Official Logo
International Journal ofAyurvedic and Herbal Medicine
arrow_backBack to Issue
arrow_backPrevious Article
Next Articlearrow_forward

Genetic factor of Depression-concept of Ayurvedic management

Published:15 Aug 2013
visibility0 Viewsdownload0 Downloads
Rinki K. Verma1*, Aruna Agrawal2, G.P.Dubey2

1 Department of kriya Sharir,Faculty of Ayurveda, Institute of Medical Sciences, B.H.U. Varanasi (U.P)221005: INDIA; Institute of medical Sciences, Banaras Hindu University, Varanasi UP, India

2 Department of kriya Sharir,Faculty of Ayurveda, Institute of Medical Sciences, B.H.U. Varanasi (U.P)221005: INDIA

Corresponding Author:Rinki K. Verma

picture_as_pdfDownload link10.47191/ijahm/v3i4.05

subjectAbstract

Globally, depression, one of the neurological disorders has been described as millennia linked with neurobiology associated with direct neurochemicals and biochemical incredible factors interact with “gene- gene”, “gene -environment”as long as a scaffold for future for better exploration. For the depth knowledge and management of depression we can consult with traditional Indian medicine system i.e. Ayurveda. According to Ayurveda the term depression is correlated with Vishada (Depression=Vishada). In the manner of conceptual and etymological study of depression, Ayurveda has firstly described depression as Vishada means depressed mood. Ayurvedic Acharyas described depression at many places as one of the symptoms of a various diseases and etiological factor of many psychological as well as physical diseases. In this review article we have outlined the upshot of altered regulation of particular neuro-chemical markers, molecular biology, genetics with significant role of Ayurveda which has great evidence to study the mechanisms, plasticity and neuronal survival in depression and biggest impact of Indian classical therapy in the management of depression.

sellKeywords

DepressionClock geneCOMT geneDISC-1 geneGeneticsMTHFR geneNRG-1 genePolymorphism

format_list_numberedReferences

  1. Roeleveld, N., G. A. Zielhuis and F. Gabreels, The prevalence of mental retardation: a critical review of recent literature. Dev. Med. Child Neurol;1997, Vol.39:p.125–132
  2. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry; 2001, 62 (Suppl 16):26-31
  3. World Health Organization, World suicide prevention day, 2012.
  4. Brody TM,Frazer A, MorilakD. Drugs for the treatment of affective (mood) disorders. In, Larner J,Minneman KP, eds. Human pharmacology: molecular to clinical, third ed. St. Louis: Mosby; 1998,p.349–363.
  5. Wender PH, Kety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde I. Psychiatric disorders in thebiological and adoptive families of adoptedindividuals with affective disorders.Arch Gen Psychiatry;1986,vol. 43:p.923–929.
  6. Sullivan PF, Neale MC, Kendler KS: Genetic epidemiology of major depression: review and metaanalysis.Am J Psychiatry; 2000; vol.157:p.1552–1562.
  7. Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ. A longitudinal twin study of personality andmajor depression in women. Arch GenPsychiatry, 1993b,vol.50:p-853–862.
  8. Kinsbourne, M., and W. D. Graf.Disorders of mental develop-ment in Child Neurology. edited by J. H. Menkes and H. B. Sarnat. Lippincott Williams & Wilkins, Philadelphia; 2000,p.1155–1211.
  9. Marazita ML, Neiswanger K, Cooper M, Zubenko GS, Giles DE, Frank E, et al. Genetic segregationanalysis of early-onset recurrent unipolardepression. Am J Hum Genetics; 1997, vol.61:p.1370-1378.
  10. Douglas F. Levinson. The Genetics of Depression: A Review. BIOL PSYCHIATRY 2005.
  11. Bierut LJ, Heath AC, Bucholz KK, Dinwiddie SH, Madden PAF, Statham DJ, et al ;Major depressivedisorder in a community-based twin sample. Are there different genetic and environmental contributionsfor men and women? Arch Gen Psychiatry, 1999,vol.56:p.557–563.
  12. Kendler KS, Thornton LM, Prescott CA. Gender differences in the rates of exposure to stressful lifeevents and sensitivity to their depressogenic effects. Am J Psychiatry, 2001,vol.158:p.587-593.
  13. Karestan C. Koenen,Qiang J. Fu4, Karen Ertell, Michael J. Lyons,Seth A. Eisen, William R. True JackGoldberg and Ming T. Tsuang.Common Genetic Liability to Major Depression and Posttraumatic StressDisorder in Men. J Affect Disord, 2008,vol.105(1-3):p. 109–115.
  14. Bornstein SR, Schuppenies A, Wong ML, Licinio J. Approaching the shared biology of obesity anddepression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry, 2006,vol.11:p.892–902.
  15. Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry 2000,vol. 61:p. 7–11.
  16. Fava M, Kendler KS. Major depressive disorder. Neuron; 2000,vol. 28:p.335–341.
  17. Nielsen J, Hreidarsson AB, Christensen KR. D–D translocations in patients with mental illness.Hereditas Nielsen, 1973,vol.75:p.131–135.
  18. Muller MB, Holsboer F. Mice with mutations in the HPA-system as models for symptoms of depression.Biol Psychiatry, 2006,vol. 59:p. 1104–1115.
  19. Monroe SM, Reid MW. Gene–environment interactions in depression research: genetic polymorphismsand life-stress polyprocedures. Psychol Sci, 2008,vol.19:p. 947–956.
  20. Dennis S Charney,Gregor Hasler, Wayne C Drevets1 andHusseini K Manji. Discovering Endophenotypes for Major Depression.Neuropsychopharmacology 2004,vol.29:p.1765–1781.
  21. Dulawa, S.C., Holick, K.A., Gundersen, B., and Hen, R. Effects of chronic fluoxetine in animal modelsof anxiety and depression. Neuropsychopharmacology ,2004,vol.29:p.1321-1330.
  22. Basant K.Tiwray. The severity of mental disorders is linked to interaction among candidate genes.Integr. Biol., 2012, vol.4:p. 1096-1101
  23. Hogenesch JB, Gu YZ, Jain S, Bradfield CA. The basic-helix-loop-helix- PAS orphan MOP3 formstranscriptionally active complexes with circadian and hypoxia factors. Proc Natl Acad Sci U SA;1998,vol.95:p.5474-5479.
  24. 24.Jeffery DR, Roth JA. Characterization of membrane-bound and soluble catechol-O-methyltransferase from human frontal cortex. J Neurochem, 1984,vol.42:p.826–832.
  25. Albrecht U, Zheng B, Larkin D, Sun ZS, Lee CC. MPer1 and mper2 are essential for normal resetting ofthe circadian clock. J Biol Rhythms,2001,vol.16:p.100-104.
  26. Sato TK, Panda S, Miraglia LJ, Reyes TM, et al. A functional genomics strategy reveals Rora as acomponent of the mammalian circadian clock.Neuron, 2004,vol.43:p.527-537.
  27. Iitaka C, Miyazaki K, Akaike T, Ishida N. A role for glycogen synthase kinase- 3beta in the mammaliancircadian clock. J Biol Chem,2005,vol.280:p.29397-29402.
  28. Godinho SI, Maywood ES, Shaw L, et al. The after-hours mutant reveals a role for Fbxl3 in determiningmammalian circadian period. Science,2007,vol.316:p.897-900.
  29. Siepka SM, Yoo SH, Park J, et al. Circadian mutant Overtime reveals Fbox protein FBXL3 regulation ofcryptochrome and period gene expression. Cell,2007,vol.129:p.1011-1023.
  30. Nakahata Y et al. Signaling to the circadian clock: plasticity by chromatin remodeling. Curr Opin CellBiol, 2007,vol.19:p.230–237.
  31. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem, 1958, vol.233:p.702–705.
  32. 32.. Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I. Genomic organizationof the human catechol-Omethyltransferase gene and its expression from two distinct promoters. Eur JBiochem, 1994,vol.223:p.1049–1059.
  33. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S et al. Functional analysis of geneticvariation in catechol-Omethyltransferase (COMT): effects on mRNA, protein, and enzyme activity inpostmortem human brain. Am J Hum Genet, 2004,vol.75:p.807–8
  34. Gogos, J., Morgan, M., Luine, V., Santha, M. O., Plaff, D., & Karayiorgou, M. Catechol-Omethyltransferase-deficient mice exhibit sexually dimorphicchanges in catecholamine levels andbehavior. Proceedings of the National Academy of Science,1998,vol.95:p.9991–9996.
  35. Guldberg, H., & Marsden, C. Catechol-O-methyl transferase: Pharmacological aspects and physiologicalrole. Pharmacology Reviews,1975,vol.27:p. 135–206.
  36. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J: Kinetics of human solubleand membrane-bound catechol-O-methyltransferase: a revised mechanism anddescription of thethermolabile variant of the enzyme. Biochemistry, 1995, vol. 34:p.4202-10.
  37. Nutt, D. J. The role of dopamine and norepinephrine in depression and antidepressant treatment. Journalof Clinical Psychiatry,2006,vol.67:p. 3–8.
  38. Nakata K, Lipska BK, Hyde TM, Ye T, Newburn EN, Morita Y, Vakkalanka R, Barenboim M, Sei Y,Weinberger DR, Kleinman JE."DISC1 splice variants are upregulated in schizophrenia and associatedwith risk polymorphisms". Proc Natl Acad Sci U S A; 2009,vol. 106 :p. 15873–8
  39. Huotari M, Santha M, Lucas LR, Karayiorgou M, Gogos JA, Mannisto PT et al. Effect of dopamineuptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferasedisruptedmice. J Pharmacol Exp Ther,2002,vol.303:p.1309–1316.
  40. Le Strat Y, Ramoz N, Gorwood P "The role of genes involved in neuroplasticity and neurogenesis in theobservation of a gene-environment interaction (GxE) in schizophrenia". Curr. Mol. Med,2009,vol.9:p.506-18
  41. Millar, J.K., Wilson-Annan, J.C., Anderson, S., Christie, S., Taylor, M.S., Semple, C.A., Devon, R.S.,Clair, D.M., Muir, W.J., Blackwood, D.H. et al.Disruption of two novel genes by a translocation cosegregatingwith schizophrenia. Hum. Mol. Genet.,2000,vol.9:p.1415–1423.
  42. Sequeira A, Turecki G .Genome wide gene expression studies in mood disorders. OMICS, (2006), 10p.:444-454.
  43. Hamosh, A., A. F. Scott, J. Amberger, C. Bocchini, D. Valle et al., Online Mendelian Inheritance in Man(OMIM), a knowledge base of human genes and genetic disorders. Nucleic Acids Res., 2002,vol.30:p..52–55.9-382
  44. Gaysina, D., Cohen, S., Craddock, N., Farmer, A., Hoda, F., Korszun, A., Owen, M.J., Craig, I.W.,McGuffin, P.,. No association with the 5,10- methylenetetrahydrofolate reductase gene and majordepressive disorder: results of the depression case control (DeCC) study and a meta-analysis. Am. J.Med. Genet. B Neuropsychiatr. Genet, 2008,vol.147B:p. 699–706.
  45. Frosst P, Blom HJ, Milos R, Goyette P Sheppard CA, Matthews RG, Boers GJ, den Heijer M,Kluijtmans LA, van den Heuvel LP. A candidate genetic risk factor for vascular disease: a commonmutation in methylenetetrahydrofolate reductase. Nat Genet, 1995,vol.10:p. 111-113.
  46. Harrison PJ, Weinberger DR (2005): Schizophrenia genes, gene expression, and neuropathology:Onthematter of their convergence. Mol Psychiatry 10:40–68.Davis KL, Stewart DG, Friedman JI, BuchsbaumM, Harvey PD, Hof PR, et al.White matter changes in schizophrenia: Evidence for myelinrelated dysfunction. Arch Gen Psychiatry,2003,vol. 60:p.443-456.
  47. Lachman H, Pedrosa E, Ye K, Nolan K, Saito T.Analysis of polymorphisms in AT-rich domains ofneuregulin 1 gene in schizophrenia [Abstract].Am J Med Genet,2005,vol. 138B:p.87.
  48. Van der Put, N.M., Gabreels, F., Stevens, E.M., Smeitink, J.A., Trijbels, F.J., Eskes, T.K., van denHeuvel, L.P., Blom, H.J.,. A second common mutation in the methylenetetrahydrofolate reductase gene:an additional risk factor for neuraltube defects? Am. J. Hum. Genet, 1998,vol.62:p. 1044–1051.
  49. Sazci, A., Ergul, E., Kucukali, I., Kara, I., Kaya, G. Association of the C677T and A1298Cpolymorphisms of methylenetetrahydrofolate reductase gene with schizophrenia: association issignificant in men but not in women. Prog. Neuropsychopharmacol. Biol. Psychiatry,2005 ,vol.29:p.1113–1123.
  50. Zintzaras, E., C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms inschizophrenia, bipolar disorder and depression: a metaanalysis of genetic association studies. Psychiatr.Genet., 2006,vol.16:p.105–115.
  51. Stahl SM. CNS Spectr. 2010,vol.15.:p.220-30.
  52. Gueant JL, Anello G, Bosco P, et al. Homocysteine and related genetic polymorphisms in Down“ssyndrome IQ. J Neurol Neurosurg Psychiatry, 2005.,vol. 76p.:706–709.
  53. Matté C et al. Neuroscience, 2009,vol.163(4):p.1039-45.
  54. Jacobsson, B. & Hagberg, G. Antenatal risk factors for cerebral palsy. Best Pract. Res.,2004,vol.18:p.425-436.
  55. Davalos I-P, Olivares N, Castillo M-T, et al.. The C677T polymorphismof the methylenetetrahydrofolategene in Mexican mestivoneural-tube defect parents, control mestivo and native populations.Annales deGenetique, 2000,vol. 43:p.89–92.
  56. Caspersson T, Farber S, Foley GE, Kudynowski J, Modest EJ, Simonsson E et al. Chemicaldifferentiation along metaphase chromosomes. Exp Cell Res Caspersson, 1968,vol.49:p.219–222.
  57. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. Highresolution haplotype structure in thehuman genome. Nat Genet, 2001,vol.29: p.229–232.
  58. Migaud M, Charlesworth P, Dempster M, Webster LC, Watabe AM, Makhinson M et al. Enhancedlong-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein.Nature, 1998,vol.396: p.433-439.
  59. Stahl SM. Basic psychopharmacology of antidepresssants, Part I: Antidepressants have seven distinctmechanisms of action. J Clin Psychiatry,1998,vol.59:p.5-14.]
  60. Bodkin, J. Alexander; Zornberg, Gwen L.; Lukas, Scott E.; Cole, Jonathan O. "Buprenorphine Treatmentof Refractory Depression". Journal of Clinical Psychopharmacology, 1995,vol. 15:p. 49–57.
  61. Ghadirian, AM; Murphy, BE; Gendron, MJ. "Efficacy of light versus tryptophan therapy in seasonalaffective disorder". Journal of Affective Disorders,1998,vol.50:p. 23–7.
  62. Vega, Jason A. Wheeler; Mortimer, Ann M.; Tyson, Philip J. "Conventional Antipsychotic Prescriptionin Unipolar Depression, I". The Journal of Clinical Psychiatry,2003,vol.64:p. 568–74.
  63. Furukawa, Toshi A; Streiner, David; Young, L. Trevor; Kinoshita, Yoshihiro."Antidepressants plusbenzodiazepines for major depression". In Furukawa, Toshi A. Cochrane Database of SystematicReviews, 2001, (2).
  64. Warner-Schmidt, Jennifer L.; Duman, Ronald S. "Hippocampal neurogenesis: Opposing effects of stressand antidepressant treatment". Hippocampus,2006,vol.16 (3):p. 239–49.
  65. Carboni, Lucia; Vighini, Miriam; Piubelli, Chiara; Castelletti, Laura; Milli, Alberto; Domenici, Enrico."Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists". European Neuropsychopharmacology,2006,vol.16:p.521–37.
  66. Keers R, Uher R. Gene-environment interaction in major depression and antidepressant treatmentresponse.Curr Psychiatry Rep, 2012,vol.14:p.129-37.
  67. Uz, T. Ahmed, R.; Akhisaroglu, M.; Kurtuncu, M.; Imbesi, M.; Dirim Arslan, A.; Manev, H. "Effect offluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum".Neuroscience, 2005,vol.34 (4):p.1309–16.
  68. Manev, Hari; Uz, Tolga; Smalheiser, Neil R; Manev, Radmila. Antidepressants alter cell proliferationin the adult brain in vivo and in neural cultures in vitro". European Journal of Pharmacology,2001,vol.411:p. 67–70.
  69. Pariante, CM. "Depression, stress and the adrenal axis". Journal of neuroendocrinology, 2003, vol.15:p.811-2.
  70. Sambunaris A, Hesselink JK, Pinder R, Panagides J, Stahl SM.. Development of new antidepressants. JClin Psychiatry, 1997,vol.5:p.40-53.
  71. Heath D Schmidt,, Richard C Shelton2 and Ronald S Duman Functional Biomarkers of Depression:Diagnosis, Treatment,and Pathophysiology. Neuropsychopharmacology,2011,vol.36:p.2375–2394
  72. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in majordepressive disorder. Mol Psychiatry,2010,vol.15:p.473–500.
  73. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, Ackenheil M .Single nucleotide polymorphismand haplotype analysis of anovel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. BiolPsychiatry 2004b,vol.56:p.581–586.
  74. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, Bader M Synthesis of serotonin bya second tryptophan hydroxylase isoform. Science ,2003,vol.299:p.76.
  75. Manev, Hari; Uz, Tolga; Smalheiser, Neil R; Manev, Radmila "Antidepressants alter cell proliferation inthe adult brain in vivo and in neural cultures in vitro". European Journal ofPharmacology,2001,vol.411:p.67–70.
  76. Zhang, Han-Ting; Huang, Ying; Mishler, Kathleen; Roerig, Sandra C.; O'Donnell, James M. "Interactionbetween the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDEinhibitor rolipram in rats". Psychopharmacology,2005,vol.182:p. 104–15.
  77. Zhou D, Jin H, Lin HB, Yang XM, Cheng YF, Deng FJ, Xu JP. Antidepressant effect of the extractsfrom Fructus akebiae. Pharmacol Biochem Behav,2010,vol.94:p.488-495.

How to Cite

Verma, R. K., Agrawal, A., & G.P.Dubey (2013). Genetic factor of Depression-concept of Ayurvedic management. International Journal of Ayurvedic and Herbal Medicine, 3(4). https://doi.org/10.47191/ijahm/v3i4.05

APA

American Psychological Association Style

arrow_back
Previous ArticleHerbs in Inflammation - A Review
Next ArticleAnexploratorydescriptionofpīnas Roga(Allergic Rhinitis)Described Insrilankantraditional Medicine
arrow_forward